Bristol-Myers Squibb: Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment

Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its immunotherapy drug Opdivo (nivolumab), marking a major step towards expanding treatment options for patients with resectable non-small cell lung cancer (NSCLC) in the EU. CHMP, part of the European Medicines Agency (EMA), has recommended [...] The post Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment appeared first on Pharmafile.